Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 3c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts AUPH Hot Sheet
Join SI Premium – FREE
Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.19), $0.03 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $45.1 million versus the consensus estimate of $44.2 million.
GUIDANCE:
Aurinia Pharmaceuticals sees FY2024 revenue of $200-220 million, versus the consensus of $219.1 million.
For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Preferred Bank (PFBC) Tops Q3 EPS by 4c
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
